“…Bmal1−/− mice have a significantly reduced lifespan and show signs of accelerated ageing such as sarcopenia, cataracts, less subcutaneous fat, organ shrinkage by 16-18 weeks of age, presumably as a consequence of highly elevated levels of reactive oxygen species (ROS) (Kondratov, Kondratova, Gorbacheva, Vykhovanets, & Antoch, 2006). Moreover, Bmal1−/− mice exhibit severe cognitive deficits (Kondratov et al, 2006;Kondratova, Dubrovsky, Antoch, & Kondratov, 2010) and impaired adult neurogenesis (Ali et al, 2015;Ali et al, 2018;Bouchard-Cannon, Mendoza-Viveros, Yuen, Kaern, & Cheng, 2013). In the brain of 10-15 weeks old Bmal1−/− mice astrocytosis starts to develop, as evidenced by an increased expression of glial fibrillary acidic protein (GFAP) (Musiek et al, 2013) and by the age of 24 weeks, synaptic terminals are degenerated and cortical functional connectivity is affected (Musiek et al, 2013).…”